Sage sues Biogen as analyst detects little interest in buyout at original offer price

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner.

The lawsuit is sealed in Delaware’s Court of Chancery, but in a separate filing, Sage said it’s “seeking preliminary injunctive relief to enforce a standstill agreement and a trial on a paper record on an expedited basis,” according to Bloomberg Law.